⏳ Fetching live dividend data...
Home › Calculator › ABBV Dividend Calculator 2026
AbbVie Inc. · NYSE
Price: $206.60 · Annual div: $6.74/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in ABBV → $180.5K in 10 years · $1,523.82/month
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open ABBV position with:
Real after-tax yield depends on where you live and how you hold ABBV.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 3.26% | 0.46% | $326 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 2.77% | -0.03% | $277 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 2.61% | -0.19% | $261 / yr |
| 🇬🇧 UK ISA | 0% | 3.26% | 0.46% | $326 / yr |
| 🇬🇧 UK Taxable | 8.75% | 2.97% | 0.17% | $297 / yr |
| 🇨🇦 TFSA | 0% | 3.26% | 0.46% | $326 / yr |
| 🇨🇦 CA Taxable | 25% | 2.44% | -0.35% | $245 / yr |
| 🇦🇺 Super (pension) | 15% | 2.77% | -0.03% | $277 / yr |
| 🇦🇺 AU Taxable | 30% | 2.28% | -0.52% | $228 / yr |
| 🇩🇪 DE Taxable | 26.375% | 2.40% | -0.40% | $240 / yr |
| 🇫🇷 FR Taxable | 30% | 2.28% | -0.52% | $228 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $6.74/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
ABBV pays quarterly — 4 times per year. Next ex-div: TBD.
How ABBV compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ABBV sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-03-31 | 71 | $217.49 | $15.4K | ||
| A-Award | 2026-03-31 | 155 | $217.49 | $33.7K | ||
| A-Award | 2026-03-31 | 35 | $217.49 | $7.6K | ||
| F-InKind | 2026-02-27 | 2,108 | $232.08 | $489.2K | ||
| Sale | 2026-03-04 | 5,230 | $233.56 | $1.22M | ||
| F-InKind | 2026-02-27 | 1,594 | $232.08 | $369.9K | ||
| F-InKind | 2026-02-27 | 8,037 | $232.08 | $1.87M | ||
| F-InKind | 2026-02-27 | 36,523 | $232.08 | $8.48M | ||
| F-InKind | 2026-02-27 | 23,812 | $232.08 | $5.53M | ||
| F-InKind | 2026-02-27 | 14,850 | $232.08 | $3.45M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ABBV dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“AbbVie DRIP calculator with payout ratio analysis. The high payout ratio concerned me, but the free cash flow score section gave me reassurance. This is the depth I was looking for.”
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →